Skip Navigation

Karmanos Cancer Center

Bone Marrow Transplant
4100 John R.
Second Floor HP02BF
Detroit, MI 48201
(313) 576-9101
(800) KARMANOS
http://www.karmanos.org/BMT

Number of Transplants Performed

This center has been performing allogeneic transplants since 1987 and has been an NMDP transplant center since August 1992.

Transplants Reported (From Jan. 2011 to Dec. 2012 as reported by the centers)       Unrelated or Related Donor Auto-
logous

(PBSC or marrow)
Total (by transplant type)
Marrow PBSC Cord
Blood
Unrelated Donor
- Adult
11 144 0 --- 155
Unrelated Donor
- Pediatric
0 0 0 --- 0
Related Donor
- Adult
5 64 0 --- 69
Related Donor
- Pediatric
0 0 0 --- 0
Autologous
- Adult
--- --- --- 321 321
Autologous
- Pediatric
--- --- --- 0 0
Total
(by cell source)
16 208 0 321 545

To find centers that perform cord blood transplants, use the Search Tool on this site.


Patient Survival Information for this Center

Wayne State University Hospital


This center's actual 1-year survival results are above the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2009, 2010 and 2011, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 309 patients.

The actual 1-year survival of these patients is 61.1%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 50.1% and 60.7%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).


Transplant Results by Patient's Age, Disease Type and Stage

Karmanos Cancer Center - Related

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission -- -- 1/1 2/2 1/1 -- -- 4/4
Acute lymphoblastic leukemia in second complete remission -- -- -- -- -- 1/1 0/1 1/2
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- -- 0/1 -- 2/2 -- 1/1 3/4
Acute myelogenous leukemia in first complete remission -- -- -- 1/1 4/4 8/10 4/6 17/21
Acute myelogenous leukemia in second complete remission -- -- -- -- 1/1 1/2 2/2 4/5
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- -- -- -- 0/2 1/3 1/2 2/7
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- 0/1 3/4 2/3 5/8
Chronic myelogenous leukemia in first chronic phase -- -- -- -- -- 1/2 -- 1/2
Chronic myelogenous leukemia in blastic phase -- -- -- 0/1 -- -- -- 0/1
Hodgkin lymphoma -- -- 1/1 -- -- 0/1 -- 1/2
Multiple myeloma / Plasma cell disorder -- -- -- -- 1/1 -- 2/3 3/4
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- -- -- -- -- 4/4 3/3 7/7
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- -- 1/1 0/1 4/4 3/3 8/9
Myelodysplastic disorders - Other MDS -- -- -- -- 1/1 -- 1/1 2/2
Myeloproliferative syndromes -- -- -- -- -- -- 1/2 1/2
Non-Hodgkin lymphoma -- -- 0/1 1/1 4/9 6/13 1/5 12/29
Severe aplastic anemia -- -- 2/2 1/1 -- 1/1 -- 4/4
Total -- -- 4/6 6/7 14/23 30/45 21/32 75/113

Karmanos Cancer Center - Unrelated

Survival by Patient's Age, Disease Type and Stage after Unrelated Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using unrelated donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission -- -- 1/2 3/3 2/2 0/2 -- 6/9
Acute lymphoblastic leukemia in second complete remission -- -- 1/1 -- 1/1 -- -- 2/2
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- -- 0/4 -- 0/1 -- -- 0/5
Acute myelogenous leukemia in first complete remission -- -- 2/4 4/6 2/4 6/6 6/8 20/28
Acute myelogenous leukemia in second complete remission -- -- 1/2 2/2 3/5 2/5 4/6 12/20
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- -- -- 2/2 2/4 4/10 3/6 11/22
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- 1/2 2/7 1/3 4/12
Chronic myelogenous leukemia in first chronic phase -- -- -- -- 0/1 2/2 -- 2/3
Chronic myelogenous leukemia in accelerated phase or second chronic phase -- -- -- -- 1/1 -- 0/1 1/2
Chronic myelogenous leukemia in blastic phase -- -- -- -- -- 0/1 -- 0/1
Hodgkin lymphoma -- -- -- 0/1 -- -- -- 0/1
Inherited abnormalities of erythrocyte differentiation or function -- -- 0/1 -- -- -- -- 0/1
Multiple myeloma / Plasma cell disorder -- -- 1/1 -- 2/3 1/4 0/1 4/9
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- -- -- -- 3/3 5/7 2/2 10/12
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- -- 0/1 0/2 1/1 1/5 2/9
Myelodysplastic disorders - Other MDS -- -- -- -- 1/2 1/1 2/2 4/5
Myeloproliferative syndromes -- -- -- 0/1 1/2 1/3 0/2 2/8
Non-Hodgkin lymphoma -- -- -- 1/4 2/6 5/8 1/4 9/22
Severe aplastic anemia -- -- 2/2 -- -- 1/1 1/1 4/4
Total -- -- 8/17 12/20 21/39 31/58 21/41 93/175

Program Description:

Our institute provides care to patients receiving autologous, related and unrelated allogeneic, cord blood and mismatched stem cell transplants. Research efforts are aimed at preventing and treating graft-versus-host disease, targeting patient immune cells to kill cancer cells and chemotherapy dose escalation for the treatment of multiple myeloma.

Contact Information:

If you have transplant-related questions, please contact Stacey Prieur, transplant center coordinator, at (313) 576-9101 or by e-mail at prieurs@karmanos.org.

Program Type:

Adult

Attending Physicians:

(Medical Doctors)

Adult -

Lois Ayash, Divaya Bhutani, Abbinav Deol, Lawrence Lum, Voravit Ratanatharathorn, Joseph Uberti

Transplants Performed:

Marrow/PBSC, single cord, and double cord

Cord blood transplants performed on:

Adult only

Find research trials at this center here:

ClinicalTrials.gov

Estimated Search & Transplant Costs

The costs for a transplant vary greatly from center to center and depend on factors such as health insurance, disease type and disease stage of the patient, as well as center-specific billing policies. Examples of costs in the search and transplant include:

  • The amount and geographic location of donors tested
  • Testing needed to confirm a match
  • Processing and collecting of tissue-typing samples
  • Donor workup testing needed
  • Getting the marrow, PBSC or cord blood unit for transplant

For the best understanding of costs of transplant and follow-up for a specific transplant center, contact the center's Financial Representative.

help Explain Transplant Costs at Different Centers

Resources for financial information

If you have questions about costs and financial services at this transplant center, you can contact the center's financial representative, Linda Whitfield by e-mail at whitfiel@karmanos.org or by phone at (313) 576-9183.

Financial services at this center could include:

  • Health insurance information
  • Financial assistance
  • Patient-related resources

Additional Information

Further information about this center, including the number and type of transplants performed in each of the last three years, and the support groups offered, may be found in the BMT InfoNet Transplant Center Directory:
http://www.bmtinfonet.org/transplantcenters.

BMT InfoNet (Blood & Marrow Transplant Information Network) is a nonprofit organization that provides information and emotional support to transplant patients and their families.